Skip to main content
Top
Published in: Diabetologia 10/2014

01-10-2014 | Article

Durable change in glycaemic control following intensive management of type 2 diabetes in the ACCORD clinical trial

Authors: Zubin Punthakee, Michael E. Miller, Debra L. Simmons, Matthew C. Riddle, Faramarz Ismail-Beigi, David J. Brillon, Richard M. Bergenstal, Peter J. Savage, Irene Hramiak, Joseph F. Largay, Ajay Sood, Hertzel C. Gerstein, for the ACCORD Group of Investigators

Published in: Diabetologia | Issue 10/2014

Login to get access

Abstract

Aims/hypothesis

We aimed to determine the persistence of glycaemic control 1 year after a limited period of intensive glycaemic management of type 2 diabetes.

Methods

4119 ACCORD Trial participants randomised to target HbA1c <6.0% (42 mmol/mol) for 4.0 ± 1.2 years were systematically transitioned to target HbA1c 7.0–7.9% (53–63 mmol/mol) and followed for an additional 1.1 ± 0.2 years. Characteristics of participants with HbA1c <6.5% (48 mmol/mol) or ≥6.5% at transition were compared. Changes in BMI and glucose-lowering medications were compared between those ending with HbA1c <6.5% vs ≥6.5%. Poisson models were used to assess the independent effect of attaining HbA1c <6.5% before transition on ending with HbA1c <6.5%.

Results

Participants with pre-transition HbA1c <6.5% were older with shorter duration diabetes and took less insulin but more non-insulin glucose-lowering agents than those with higher HbA1c. A total of 823 participants achieved a final HbA1c <6.5%, and had greater post-transition reductions in BMI, insulin dose and secretagogue and acarbose use than those with higher HbA1c (p < 0.0001). HbA1c <6.5% at transition predicted final HbA1c <6.5% (crude RR 4.9 [95% CI 4.0, 5.9]; RR 3.9 [95% CI 3.2, 4.8] adjusted for demographics, co-interventions, pre-intervention HbA1c, BMI and glucose-lowering medication, and post-transition change in both BMI and glucose-lowering medication). Progressively lower pre-transition HbA1c levels were associated with a greater likelihood of maintaining a final HbA1c of <6.5%. Follow-up duration was not associated with post-transition rise in HbA1c.

Conclusions/interpretation

Time-limited intensive glycaemic management using a combination of agents that achieves HbA1c levels below 6.5% in established diabetes is associated with glycaemic control more than 1 year after therapy is relaxed.
Appendix
Available only for authorised users
Literature
1.
go back to reference U.K. Prospective Diabetes Study Group (1995) U.K. Prospective Diabetes Study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. Diabetes 44:1249–1258CrossRef U.K. Prospective Diabetes Study Group (1995) U.K. Prospective Diabetes Study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. Diabetes 44:1249–1258CrossRef
2.
go back to reference Ikramuddin S, Korner J, Lee WJ et al (2013) Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial. JAMA 309:2240–2249PubMedCentralPubMedCrossRef Ikramuddin S, Korner J, Lee WJ et al (2013) Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial. JAMA 309:2240–2249PubMedCentralPubMedCrossRef
3.
go back to reference Mingrone G, Panunzi S, de Gaetano A et al (2012) Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 366:1577–1585PubMedCrossRef Mingrone G, Panunzi S, de Gaetano A et al (2012) Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 366:1577–1585PubMedCrossRef
4.
go back to reference Kashyap SR, Bhatt DL, Wolski K et al (2013) Metabolic effects of bariatric surgery in patients with moderate obesity and type 2 diabetes: analysis of a randomized control trial comparing surgery with intensive medical treatment. Diabetes Care 36:2175–2182PubMedCentralPubMedCrossRef Kashyap SR, Bhatt DL, Wolski K et al (2013) Metabolic effects of bariatric surgery in patients with moderate obesity and type 2 diabetes: analysis of a randomized control trial comparing surgery with intensive medical treatment. Diabetes Care 36:2175–2182PubMedCentralPubMedCrossRef
5.
go back to reference Bradley D, Conte C, Mittendorfer B et al (2012) Gastric bypass and banding equally improve insulin sensitivity and beta cell function. J Clin Invest 122:4667–4674PubMedCentralPubMedCrossRef Bradley D, Conte C, Mittendorfer B et al (2012) Gastric bypass and banding equally improve insulin sensitivity and beta cell function. J Clin Invest 122:4667–4674PubMedCentralPubMedCrossRef
6.
go back to reference Kramer CK, Zinman B, Retnakaran R (2013) Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 1:28–34PubMedCrossRef Kramer CK, Zinman B, Retnakaran R (2013) Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 1:28–34PubMedCrossRef
7.
go back to reference Gregg EW, Chen H, Wagenknecht LE et al (2012) Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA 308:2489–2496PubMedCrossRef Gregg EW, Chen H, Wagenknecht LE et al (2012) Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA 308:2489–2496PubMedCrossRef
8.
go back to reference Wajchenberg BL (2007) Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 28:187–218PubMedCrossRef Wajchenberg BL (2007) Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 28:187–218PubMedCrossRef
9.
go back to reference Mudaliar S (2013) Choice of early treatment regimen and impact on beta-cell preservation in type 2 diabetes. Int J Clin Pract 67:876–887PubMedCrossRef Mudaliar S (2013) Choice of early treatment regimen and impact on beta-cell preservation in type 2 diabetes. Int J Clin Pract 67:876–887PubMedCrossRef
10.
go back to reference Gerstein HC, Miller ME, Byington RP et al (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545–2559PubMedCrossRef Gerstein HC, Miller ME, Byington RP et al (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545–2559PubMedCrossRef
11.
go back to reference Gerstein HC, Miller ME, Genuth S et al (2011) Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 364:818–828PubMedCrossRef Gerstein HC, Miller ME, Genuth S et al (2011) Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 364:818–828PubMedCrossRef
12.
go back to reference Buse JB, Bigger JT, Byington RP et al (2007) Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 99:21i–33iPubMedCrossRef Buse JB, Bigger JT, Byington RP et al (2007) Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 99:21i–33iPubMedCrossRef
13.
go back to reference Gerstein HC, Riddle MC, Kendall DM et al (2007) Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 99:34i–43iPubMedCrossRef Gerstein HC, Riddle MC, Kendall DM et al (2007) Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 99:34i–43iPubMedCrossRef
14.
go back to reference Gillett MJ (2009) International Expert Committee report on the role of the A1c assay in the diagnosis of diabetes: Diabetes Care 32:1327–1334. Clin Biochem Rev 30:197–200CrossRef Gillett MJ (2009) International Expert Committee report on the role of the A1c assay in the diagnosis of diabetes: Diabetes Care 32:1327–1334. Clin Biochem Rev 30:197–200CrossRef
15.
go back to reference Eilers PHC, Marx BD (1996) Flexible smoothing with B-splines and penalties. Stat Sci 11:89–121CrossRef Eilers PHC, Marx BD (1996) Flexible smoothing with B-splines and penalties. Stat Sci 11:89–121CrossRef
16.
go back to reference Weng J, Li Y, Xu W et al (2008) Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 371:1753–1760PubMedCrossRef Weng J, Li Y, Xu W et al (2008) Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 371:1753–1760PubMedCrossRef
17.
go back to reference Park S, Choi SB (2003) Induction of long-term normoglycemia without medication in Korean type 2 diabetes patients after continuous subcutaneous insulin infusion therapy. Diabetes Metab Res Rev 19:124–130PubMedCrossRef Park S, Choi SB (2003) Induction of long-term normoglycemia without medication in Korean type 2 diabetes patients after continuous subcutaneous insulin infusion therapy. Diabetes Metab Res Rev 19:124–130PubMedCrossRef
18.
go back to reference Pan XR, Li GW, Hu YH et al (1997) Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 20:537–544PubMedCrossRef Pan XR, Li GW, Hu YH et al (1997) Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 20:537–544PubMedCrossRef
19.
go back to reference Knowler WC, Barrett-Connor E, Fowler SE et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403PubMedCrossRef Knowler WC, Barrett-Connor E, Fowler SE et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403PubMedCrossRef
20.
go back to reference DeFronzo RA, Tripathy D, Schwenke DC et al (2011) Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 364:1104–1115PubMedCrossRef DeFronzo RA, Tripathy D, Schwenke DC et al (2011) Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 364:1104–1115PubMedCrossRef
21.
go back to reference Gerstein HC, Yusuf S, Bosch J et al (2006) Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368:1096–1105PubMedCrossRef Gerstein HC, Yusuf S, Bosch J et al (2006) Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368:1096–1105PubMedCrossRef
22.
go back to reference Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M (2002) Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359:2072–2077PubMedCrossRef Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M (2002) Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359:2072–2077PubMedCrossRef
23.
go back to reference Gerstein HC, Bosch J, Dagenais GR et al (2012) Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367:319–328PubMedCrossRef Gerstein HC, Bosch J, Dagenais GR et al (2012) Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367:319–328PubMedCrossRef
24.
go back to reference Riddle MC, Ambrosius WT, Brillon DJ et al (2010) Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care 33:983–990PubMedCentralPubMedCrossRef Riddle MC, Ambrosius WT, Brillon DJ et al (2010) Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care 33:983–990PubMedCentralPubMedCrossRef
Metadata
Title
Durable change in glycaemic control following intensive management of type 2 diabetes in the ACCORD clinical trial
Authors
Zubin Punthakee
Michael E. Miller
Debra L. Simmons
Matthew C. Riddle
Faramarz Ismail-Beigi
David J. Brillon
Richard M. Bergenstal
Peter J. Savage
Irene Hramiak
Joseph F. Largay
Ajay Sood
Hertzel C. Gerstein
for the ACCORD Group of Investigators
Publication date
01-10-2014
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 10/2014
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-014-3318-5

Other articles of this Issue 10/2014

Diabetologia 10/2014 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.